Nivolumab plus cabozantinib as first-line treatment for patients with aRCC – Final results 

CHECKMATE 9ER TRIAL: After a 2-year follow-up period the final overall survival analysis and updated results on efficacy and safety are ready to be presented at ASCO GU 2022.